-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $54

Benzinga·06/16/2025 19:02:39
Listen to the news
Jefferies analyst Andrew Tsai maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $125 to $54.